

RESEARCH ARTICLE

# Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis

Vidya Mave<sup>1,2\*</sup>, Aarti Kinikar<sup>1,3</sup>, Anju Kagal<sup>1,3</sup>, Smita Nimkar<sup>1</sup>, Hari Koli<sup>1</sup>, Sultanat Khwaja<sup>1</sup>, Renu Bharadwaj<sup>1,3</sup>, Roy Gerona<sup>4</sup>, Anita Wen<sup>4</sup>, Geetha Ramachandran<sup>5</sup>, Hemanth Kumar<sup>5</sup>, Peter Bacchetti<sup>4</sup>, Kelly E. Dooley<sup>2</sup>, Nikhil Gupte<sup>1,2</sup>, Amita Gupta<sup>1,2</sup>, Monica Gandhi<sup>4</sup>

**1** Byramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India, **2** Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, **3** Byramjee-Jeejeebhoy Government Medical College, Pune, India, **4** University of California San Francisco, San Francisco, United States of America, **5** National Institute of Research in Tuberculosis, Chennai, India

\* [vidyamave@gmail.com](mailto:vidyamave@gmail.com)



**OPEN ACCESS**

**Citation:** Mave V, Kinikar A, Kagal A, Nimkar S, Koli H, Khwaja S, et al. (2017) Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis. PLoS ONE 12 (12): e0189101. <https://doi.org/10.1371/journal.pone.0189101>

**Editor:** Katalin Andrea Wilkinson, University of Cape Town, SOUTH AFRICA

**Received:** September 5, 2017

**Accepted:** November 17, 2017

**Published:** December 7, 2017

**Copyright:** © 2017 Mave et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper.

**Funding:** This study was primarily supported by JHU CFAR NIH/NIAID fund 1P30AI094189-01A1 and 1R21AI127149-01 (P.I. Mave). Data in this manuscript in part were collected as part of the Regional Prospective Observational Research for Tuberculosis (RePORT) India Consortium. This project has been funded in whole or in part with Federal funds from the Government of India's (GOI) Department of Biotechnology (DBT), the

## Abstract

We measured hair and plasma concentrations of isoniazid among sixteen children with tuberculosis who underwent personal or video-assisted directly observed therapy and thus had 100% adherence. This study therefore defined typical isoniazid exposure parameters after two months of treatment among fully-adherent patients in both hair and plasma (plasma area under the concentration-time curve, AUC, estimated using pharmacokinetic data collected 0, 2, 4, and 6 hours after drug administration). We found that INH levels in hair among highly-adherent individuals did not correlate well with plasma AUC or trough concentrations, suggesting that each measure may provide incremental and complementary information regarding drug exposure in the context of TB treatment.

## Background

Tuberculosis (TB) is the most common cause of morbidity and mortality from an infectious agent globally [1]. Children with TB constitute 10% of the total global burden of TB with an approximate 1 million cases occurring among children younger than 15 years [1]. Maintaining adequate adherence to anti-TB drugs for a minimum of 6-months for active TB is essential (but challenging in children, the group at highest risk of TB-related mortality) [2]. Furthermore, each of the drugs in the recommended standard anti-TB treatment (ATT) regimen -isoniazid (INH), rifampicin (RIF), ethambutol (EMB) and pyrazinamide (PZA)- has a specific role in sterilizing both semi-dormant and actively multiplying mycobacterial bacilli, required for successful TB treatment outcomes [3](3). Finally, for global TB control and to reach the target of zero deaths from TB [4], it is critical to optimize existing TB prophylaxis strategies, including INH preventive therapy (IPT), specifically for children < 5years of age, who are at high risk of developing TB after household or other closely-affiliated exposure to active TB [1,2]. Maintaining adequate exposure to IPT is also a critical feature to its durable success.

Indian Council of Medical Research (ICMR), the United States National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Office of AIDS Research (OAR), and distributed in part by CRDF Global. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the DBT, the ICMR, the NIH, or CRDF Global and R03 HD061059 (P.I. Jain S/Bharadwaj R). VM, NG, SM, HK, SK, AG are also supported by the NIH BWH Clinical Trials Unit for NIAID Networks (UM1) (P.I. Flexner/ Gupta, UM1AI069465). MG, RG, and AW are supported by NIAID/NIH 2R01 AI098472 and hair assay development was partially supported by NIAID/NIH R01AI123024. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Any mention of trade names, commercial projects, or organizations does not imply endorsement by any of the sponsoring organizations. The content of this paper is solely the responsibility of the authors and does not necessary represent the official views of the funders.

**Competing interests:** The authors have declared that no competing interests exist.

Optimal drug exposure to ATT and IPT ensure killing of *Mycobacterium tuberculosis* bacilli, but best practices to measure drug exposure to anti-TB drugs remain elusive [5]. Treatment adherence as measured by adherence questionnaires and pill counts can be subject to social desirability and recall biases. Moreover, self-report or pill counts cannot capture actual drug ingestion and drug exposure [6]. Drug exposure is often measured by single plasma drug levels, but these levels represent only a small window of exposure and exhibit high rates of intra-individual variability [7,8]. Furthermore, plasma drug measurement requires skilled phlebotomists, cold chain for storage and shipment, and sampling timed to dose, limiting the use of this measure in routine clinical practice. Exposure measures from intensive pharmacokinetics (PK) studies are even more difficult to perform in clinical practice. Dried blood spot (DBS) analysis, using fingerprick sampling, is relatively simple, but this technology is still in the initial stages of development for anti-TB drugs and requires validation; moreover, the stability of some TB drugs (rifampin, isoniazid) in DBS is poor [9,10].

Hair assays of drugs have emerged as an alternate, noninvasive, innovative tool that can capture drug exposure and adherence [11]. Drugs get incorporated into hair over weeks to months and concentrations in 1cm of hair represent approximately one month of drug exposure [12]. Our group has developed expertise in the development of hair assays for antiretrovirals (ARVs) and shown multiple uses for hair ARV concentrations in the setting of HIV treatment and prevention [13–19]. Building on earlier work by Eisenhut et al [20], we have previously shown that INH can be detected in the hair of children on ATT and that INH concentrations in hair are quantifiable over a dynamic range [21, 22]. Typical ranges of INH hair concentrations in fully adherent pediatric patients have not yet been defined. In this study, we provide initial data about typical values for INH hair levels and plasma area-under-the-curve concentrations from intensive PK studies- as well as their correlation- in a cohort of HIV-infected and uninfected children on ATT under directly observed therapy.

## Methods

A prospective cohort study of children with TB was established at BJ Government Medical College (BJGMC)—Sassoon General Hospital (SGH) in Pune, India. The details of the study are described elsewhere [22]. Briefly, we enrolled children <12 years with known HIV status who were initiated on first line thrice weekly ATT following a clinically or microbiologically confirmed TB diagnosis [22]. Of these, 16 participants underwent directly observed therapy (DOT) either using in-person DOT or using video-assisted DOT to ensure 100% adherence. No participant reported vomiting or diarrhea on the day of study measurements, and all had dark brown or black hair.

For this study, semi-intensive PK studies of INH were performed by obtaining plasma samples at 0, 2, 4, and 6 hours after directly-observed ATT administration at month 2 of treatment. Plasma concentrations of INH were measured using validated high performance liquid chromatography at the National Institute for Research in Tuberculosis (NIRT), Chennai, India [23]. On the same day of the plasma PK study and also at months 4 and 6, a small thatch of hair (approximately 20 strands) was cut from the occipital region close to the scalp and from underneath the top layer of hair as previously described [9,12]. The cut hair was then placed on a piece of tin foil and taped down at its distal end (side furthest from the scalp) with a thin label to mark directionality. The specimen was then sealed inside a plastic bag containing a desiccant pellet, stored at room temperature and shipped to the University of California, San Francisco, TB Hair Analysis Laboratory for measurement of INH concentrations, as previously described [22].

The median and interquartile ranges (IQR) of INH concentrations in hair were calculated. Similarly, median and IQR of plasma concentrations (maximum concentration, or  $C_{max}$ ) and exposure (area under the concentration-time curve over 6 hours ( $AUC_{0-6}$ )) were calculated. The linear trapezoidal rule was used to compute  $AUC_{0-6}$ ;  $C_{max}$  was determined by visual inspection of data. Scatterplots were generated to compare log-transformed plasma AUC with hair concentrations. We examined the associations of plasma AUC at month 2 with hair INH levels at months 2, 4, and 6. Further, we compared plasma trough concentrations and the hair INH levels at month 2 and mean hair levels from month 2, 4 and 6 using Spearman rank correlation. The Byramjee-Jeejeebhoy Government Medical College Institutional Ethics Committee and Johns Hopkins University institutional review boards both approved the study. Parents/guardians provided written informed consent; participants, when appropriate, provided assent.

### Results

Of 16 children enrolled, the median age was 90 (IQR, 60–105) months; 5 (31%) were between 2 and <5 years of age and 11 (69%) were  $\geq 5$  years of age. Nine (56%) were female, 3 (19%) had HIV co-infection. The median weight was 19.5 (12.35–24.95) kg, and 9 (56%) reported a history of TB exposure within the last 2 years prior to enrollment; 8 (50%) had pulmonary TB and 8 (50%) were diagnosed with extrapulmonary TB (EPTB). In-person or video-recorded directly observed therapy verified 100% adherence to ATT for all 16 children.


The PK parameters from all children are shown in the [Table 1](#). The median and IQR of INH concentrations in hair for months 2, 4 and 6 were 1.15 (0.54–2.25), 1.86 (0.81–6.32) and 0.90 (0.73–1.09) ng/mg, respectively. The Wilcoxon signed-rank test gave  $p > 0.95$  for month 2 vs 4,  $p = 0.05$  for month 2 vs 6, and  $p = 0.68$  for month 4 vs 6. At 2 months, males tended to have higher INH hair values.

**Table 1. Plasma area-under-the curve (AUC) concentrations and hair concentrations of isoniazid (INH) among children with 100% adherence to tuberculosis (TB) treatment compared to females (1.64 (1.21–13.2) vs. 0.66 (0.47–1.08),  $p = 0.05$ ); INH hair levels were lower in older children (correlation = -0.42;  $p = 0.11$ ) and among children who were heavier (-0.43;  $p = 0.10$ ).**

	Age in months	Sex	Weight in kgs	HIV Positive?	Plasma AUC INH levels, mcg/ml.hrs	Hair INH levels at month 2, ng/mg
Child 1	31	M	10	Negative	20.19	39.80
Child 2	113	F	24.9	Negative	23.3775	1.24
Child 3	60	F	12.7	Negative	33.225	1.08
Child 4	26	M	8	Positive	23.7825	13.2
Child 5	102	M	25	Negative	14.9850	1.601
Child 6	115	F	26	Negative	13.7175	0.823
Child 7	31	F	11	Negative	31.2525	19.5
Child 8	68	F	20	Negative	7.9875	0.205
Child 9	60	F	12	Positive	15.72	0.664
Child 10	104	F	19	Negative	22.425	0.466
Child 11	87	M	15	Negative	19.7925	2.858
Child 12	100	F	21	Negative	26.2125	0.103
Child 13	106	M	25	Positive	15.4425	1.635
Child 14	124	M	27	Negative	34.9275	0.365
Child 15	93	M	24	Negative	30.705	1.211
Child 16	78	F	19	Negative	5.5275	0.613

Kgs = kilograms, HIV = Human immunodeficiency virus

<https://doi.org/10.1371/journal.pone.0189101.t001>



**Fig 1. Scatterplot showing 6-hour plasma area-under-the-curve isoniazid concentrations and hair isoniazid concentration (log scale) at month 2 (n = 16).**

<https://doi.org/10.1371/journal.pone.0189101.g001>

The median (IQR) AUC was 21.31 (15.21–28.46) mcg/ml.hrs. In contrast to hair levels, median plasma AUC was similar in females (22.4 (13.7–26.2) mcg/ml.hrs) and males (20.2 (15.4–30.7) mcg/ml.hrs)  $p = 0.63$ . The Fig 1 shows the scatterplot of individual hair INH levels and corresponding plasma AUC measures of INH at month 2. Plasma AUC concentrations correlated poorly with hair INH concentration at month 2 (correlation coefficient 0.09 (-0.45, 0.62)); correlations were still poor, but improved at month 4 (correlation coefficient 0.21, 95% confidence interval [CI] (-0.42, 0.84)) and month 6 (correlation coefficient 0.38 (95% CI, -0.34, 1.00)). Among males, the AUC-Hair correlation at month 2 was -0.32 (95% CI, -0.86, 0.56), while among females, it was 0.43 (95% CI, -0.33, 0.85). Plasma trough and peak levels correlated extremely poorly with hair INH levels with correlation coefficients of -0.060 (95% CI, -0.56, 0.44) and -0.25 (95% CI, -0.96, 0.47), respectively.

## Discussion

This study provides the first information about concurrently measured plasma and hair INH exposures among children with 100% adherence to ATT, as confirmed via in-person or video-assessed directly observed therapy. We found that hair levels of INH among highly-adherent

individuals had little correlation with plasma AUC, peak or trough values, with plasma collected on a single occasion using semi-intensive PK sampling.

Suboptimal TB drug exposure increases the risk of TB treatment failure, resistance, recurrence and death, especially among children and HIV-infected persons [24–28]. While previous reports have demonstrated that inadequate INH exposure contributes to poor TB treatment outcomes in high HIV burden settings [25], limited data are available on target plasma drug concentrations associated with optimal TB treatment outcomes. A commonly-used ‘target’  $C_{max}$  for INH is 3 mcg/mL, but this number is based on typical exposures seen in patients on TB treatment and not on convincing pharmacokinetic-pharmacodynamic (PK-PD) analyses. Single plasma levels, like  $C_{max}$ , may be subject to significant day-to-day variation, with AUC measures from intensive or semi-intensive PK studies serving as more robust measures of exposure. However, calculating AUC parameters from even semi-intensive PK studies is an arduous process requiring a prolonged period of observation and multiple blood draws. Moreover, drug concentrations in hair provide an estimate of longer term exposure than a single AUC measure, for about one month of drug-taking if the hair is cut to 1 centimeter from the scalp [19]. Hair is feasible to collect, since it does not require phlebotomy, biohazardous precautions or a cold-chain, and we have shown high acceptability of hair collection in studies among Indian children [22](2).

Among children with TB, where drug taking relies on administration by the parent/guardian, and where drug levels can be highly variable due to maturing metabolizing systems, therapeutic monitoring of drug levels is likely to be critical for optimizing TB treatment outcomes. Given the noninvasive nature of hair sampling and the desire to avoid phlebotomy among young children, hair levels may provide a reasonable alternative to intensive PK sampling to assess drug exposure during ATT. This study showed poor correlation between hair levels of INH and plasma PK measures from a single time point. This lack of correlation may reflect the fact that hair assesses exposure over a much longer time frame than either a single plasma measure or a 6-hour AUC measure. Also, hair concentrations are influenced by both individual PK and by adherence over time, whereas single-occasion PK sampling simply demonstrates individual PK (which may depend on age, pharmacogenetics and other factors). Therefore, the measures may provide complementary information when assessing exposure among children on ATT, in the same way that a hemoglobin A1C and short-term blood glucose value may provide different but complementary information for a patient with diabetes. AUC measurement was only performed on one occasion and only over 6 hours, compared to the 48–72-hour inter-dose intervals, so it may not accurately measure the full drug exposure that contributes to hair levels. Furthermore, similar to data by Eisenhut et al [20], we found gender differences in hair INH levels, although these did not appear to explain the poor correlation of AUC and hair levels. Finally, it is possible that INH acetylator status may have influenced both hair and plasma drug levels as previously reported [20].

A major limitation of this study is that we used a very small subset of children from a larger study. Of note, as seen in other studies, there were a few hair and plasma levels that were extremely low. Since adherence was monitored and demonstrated to be 100%, the assumption is that extremely low levels reflect inadequate drug exposure due to pharmacokinetic variability (low absorption, rapid metabolism or clearance).

Pharmacologic measures are increasingly being explored to ensure efficacy of prophylactic and therapeutic regimens in both clinical studies and routine practice. Our study shows that hair levels provide information in highly-adherent patients that is distinct from the information provided by single-occasion exposure measures. Further study is required to assess the pharmacodynamic relationship between hair levels of TB drugs and treatment or prevention

outcomes in large cohorts and the incremental value of adding hair to plasma exposure measures in these studies.

## Acknowledgments

We thank the study participants and study staff for their immense contribution.

## Author Contributions

**Conceptualization:** Vidya Mave, Aarti Kinikar, Kelly E. Dooley, Amita Gupta, Monica Gandhi.

**Data curation:** Vidya Mave, Smita Nimkar, Roy Gerona, Anita Wen, Geetha Ramachandran, Hemanth Kumar, Peter Bacchetti, Nikhil Gupte, Monica Gandhi.

**Formal analysis:** Vidya Mave, Roy Gerona, Anita Wen, Geetha Ramachandran, Hemanth Kumar, Peter Bacchetti, Nikhil Gupte, Monica Gandhi.

**Funding acquisition:** Vidya Mave, Kelly E. Dooley, Amita Gupta.

**Investigation:** Vidya Mave, Aarti Kinikar, Anju Kagal, Smita Nimkar, Renu Bharadwaj, Kelly E. Dooley, Amita Gupta, Monica Gandhi.

**Methodology:** Vidya Mave, Aarti Kinikar, Anju Kagal, Renu Bharadwaj, Roy Gerona, Anita Wen, Geetha Ramachandran, Hemanth Kumar, Kelly E. Dooley, Amita Gupta, Monica Gandhi.

**Project administration:** Vidya Mave, Aarti Kinikar, Anju Kagal, Smita Nimkar, Hari Koli, Sultanat Khwaja, Renu Bharadwaj.

**Resources:** Vidya Mave, Aarti Kinikar, Hari Koli, Sultanat Khwaja, Kelly E. Dooley, Amita Gupta, Monica Gandhi.

**Software:** Peter Bacchetti, Nikhil Gupte.

**Supervision:** Vidya Mave, Aarti Kinikar, Anju Kagal.

**Validation:** Peter Bacchetti, Nikhil Gupte.

**Visualization:** Peter Bacchetti, Nikhil Gupte.

**Writing – original draft:** Vidya Mave, Aarti Kinikar, Anju Kagal, Renu Bharadwaj, Roy Gerona, Anita Wen, Geetha Ramachandran, Hemanth Kumar, Peter Bacchetti, Kelly E. Dooley, Nikhil Gupte, Amita Gupta, Monica Gandhi.

**Writing – review & editing:** Aarti Kinikar, Anju Kagal, Smita Nimkar, Hari Koli, Sultanat Khwaja, Renu Bharadwaj, Roy Gerona, Anita Wen, Geetha Ramachandran, Hemanth Kumar, Peter Bacchetti, Kelly E. Dooley, Nikhil Gupte, Amita Gupta, Monica Gandhi.

## References

1. World Health Organization. Global tuberculosis report 2016. [http://www.who.int/tb/publications/global\\_report/en/](http://www.who.int/tb/publications/global_report/en/). Accessed 20th October 2016.
2. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. *Int J Tuberc Lung Dis*. 2004 Apr; 8(4):392–402 PMID: [15141729](https://pubmed.ncbi.nlm.nih.gov/15141729/)
3. DA M. The Action Of Antituberculosis Drugs In Short-Course Chemotherapy. *Tubercle*. 1985; 66(3):219–25. PMID: [3931319](https://pubmed.ncbi.nlm.nih.gov/3931319/)
4. World Health Organization. Roadmap for Childhood TB: Toward Zero Deaths. <http://www.who.int/tb/publications/tb-childhoodroadmap/en/>.

5. Peloquin C. The Role of Therapeutic Drug Monitoring in Mycobacterial Infections. *Microbiology spectrum*. 2017;5(1).
6. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. *HIV Clin Trials*. 2008; 9(4):238–46. <https://doi.org/10.1310/hct0904-238> PMID: 18753118
7. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. *Clin Infect Dis*. 2012 Jul; 55(2):169–77. <https://doi.org/10.1093/cid/cis353> PMID: 22467670
8. Garcia-Martin E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. *Current drug metabolism*. 2008; 9(6):487–97. PMID: 18680468
9. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. *Ther Drug Monit*. 2009; 31(3):327–36. <https://doi.org/10.1097/FTD.0b013e31819e91ce> PMID: 19349929
10. Alffenaar JW. Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs. *J Infect Dis*. 2012 Jun; 205(11):1765–6. Author reply. <https://doi.org/10.1093/infdis/jis270> PMID: 22459734
11. Gandhi M, Greenblatt RM. Hair it is: the long and short of monitoring antiretroviral treatment. *Ann Intern Med*. 2002; 137(8):696–7. PMID: 12379072
12. Tsatsakis AM, Psillakis T, Paritsis N. Phenytoin concentration in head hair sections: a method to evaluate the history of drug use. *J Clin Psychopharmacol*. 2000; 20(5):560–73. PMID: 11001242
13. Hickey MD, Salmen CR, Tessler RA, Omollo D, Bacchetti P, Magerenge R, et al. Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. *J Acquir Immune Defic Syndr*. 2014 Jul 1; 66(3):311–5. <https://doi.org/10.1097/QAI.000000000000154> PMID: 24694932
14. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, et al. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. *J Acquir Immune Defic Syndr*. 2013 Aug 15; 63(5):578–84 <https://doi.org/10.1097/QAI.0b013e31829c48ad> PMID: 24135775
15. Gandhi M, Ameli N, Bacchetti P, Gange SJ, Anastos K, Levine A, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. *AIDS (London, England)*. 2009; 23(4):471–8.
16. Gandhi M, Glidden DV, Liu A, Anderson PL, Horng H, Defechereux P, et al. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. *J Infect Dis*. 2015 Nov 1; 212(9):1402–6. <https://doi.org/10.1093/infdis/jiv239> PMID: 25895984
17. Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. *Clin Infect Dis*. 2011 May; 52(10):1267–75 <https://doi.org/10.1093/cid/cir131> PMID: 21507924
18. Baxi SM, Greenblatt RM, Bacchetti P, Jin C, French AL, Keller MJ, et al. Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients. *PloS one*. 2015; 10(6):e0129100. <https://doi.org/10.1371/journal.pone.0129100> PMID: 26053176
19. Gandhi M, Greenblatt RM, Bacchetti P, Jin C, Huang Y, Anastos K, et al. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. *J Infect Dis*. 2012 Nov; 206(9):1453–61. <https://doi.org/10.1093/infdis/jis508> PMID: 22927450
20. Eisenhut M, Thieme D, Schmid D, Fieseler S, Sachs H. Hair Analysis for Determination of Isoniazid Concentrations and Acetylator Phenotype during Antituberculous Treatment. *Tuberc Res Treat*. 2012; 2012:327027 <https://doi.org/10.1155/2012/327027> PMID: 23091716
21. Gerona R, Wen A, Chin AT, Koss CA, Bacchetti P, Metcalfe J, et al. Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis. *PloS one*. 2016; 11(5):e0155887. <https://doi.org/10.1371/journal.pone.0155887> PMID: 27191185
22. Mave V, Chandanwale A, Kinikar A, Khadse S, Kagal A, Gupte N, et al. Isoniazid hair concentrations in children with tuberculosis: a proof of concept study. *Int J Tuberc Lung Dis*. 2016 Jun; 20(6):844–7 <https://doi.org/10.5588/ijtld.15.0882> PMID: 27155191
23. Hemanth Kumar AK SV, Ramachandran G. Simple and rapid liquid chromatography method for simultaneous determination of isoniazid and pyrazinamide in plasma. *SAARC J Tuberc Lung Dis HIV/AIDS* 2012; 9:13–8.

24. Hemanth Kumar AK, Narendran G, Kumar RS, Ramachandran G, Sekar L, Raja K, et al. RMP exposure is lower in HIV-infected TB patients receiving intermittent than daily anti-tuberculosis treatment. *Int J Tuberc Lung Dis*. 2015 Jul; 19(7):805–7. <https://doi.org/10.5588/ijtld.14.0702> PMID: 26056105
25. Ramachandran G, Kumar AK, Bhavani PK, Kannan T, Kumar SR, Gangadevi NP, et al. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. *Antimicrob Agents Chemother*. 2015 Feb; 59(2):1162–7. <https://doi.org/10.1128/AAC.04338-14> PMID: 25487804
26. Wiltshire CS, Lamorde M, Scherrer A, Musaazi J, Corti N, Allan B, et al. Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda. *J Int AIDS Soc*. 2014 Nov 2; 17(4 Suppl 3):19585.
27. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. *Clin Infect Dis*. 2009 Jun 15; 48(12):16
28. Swaminathan S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, Srivastava S, Deshpande D, et al. Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests. *Clin Infect Dis*. 2016 Nov 1; 63(suppl 3):S63–S74. <https://doi.org/10.1093/cid/ciw471> PMID: 27742636